Secondary
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric patients.
Symbol
FENC
Last Closing Price
$8.99
Effective Date
December 8, 2017
Underwriters
Wedbush PacGrow
To view the prospectus for Fennec Pharmaceuticals, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277